<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01824225</url>
  </required_header>
  <id_info>
    <org_study_id>NihonU-2</org_study_id>
    <nct_id>NCT01824225</nct_id>
  </id_info>
  <brief_title>Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration</brief_title>
  <official_title>Study of PRN and Every 2months Intravitreal Aflibercept After 3 Initial Monthly Injection for Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon University</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate a treatment result of every two months versus as needed (PRN) after 3 initial
      monthly intravitreal aflibercept for the Japanese age related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual acuity after treatment by PRN or 2 months intravitreal Aflibercept</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>PRN injection of aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal aflibercept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two months injection of aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal afilibercept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <arm_group_label>PRN injection of aflibercept</arm_group_label>
    <arm_group_label>Two months injection of aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of age-related macular degeneration

        Exclusion Criteria:

          -  Any treatment before intravitreal Aflibercept for age-related macular degeneration.

          -  Visual acuity above 0.1 in decimal visual acuity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuko Yuzawa, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Surugadai Nihon University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surugadai Nihon university hospital</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>April 3, 2013</lastchanged_date>
  <firstreceived_date>March 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nihon University</investigator_affiliation>
    <investigator_full_name>Koji Tanaka</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>aflibercept</keyword>
  <keyword>intravitreal injection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
